These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16710557)

  • 1. Report of the Commission on Intellectual Property Rights, Innovation and Public Health: an industry perspective.
    Noehrenberg E
    Bull World Health Organ; 2006 May; 84(5):419-20. PubMed ID: 16710557
    [No Abstract]   [Full Text] [Related]  

  • 2. WHO Intergovernmental Working Group on public health, innovation and intellectual property.
    Jones TM
    Lancet; 2010 Jul; 376(9734):21. PubMed ID: 20609985
    [No Abstract]   [Full Text] [Related]  

  • 3. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
    Velasquez G
    Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health, innovation and intellectual property rights: unfinished business.
    Türmen T; Clift C
    Bull World Health Organ; 2006 May; 84(5):338. PubMed ID: 16710532
    [No Abstract]   [Full Text] [Related]  

  • 5. CIPIH report: main recommendations.
    Bull World Health Organ; 2006 May; 84(5):351. PubMed ID: 16710542
    [No Abstract]   [Full Text] [Related]  

  • 6. Report of the Commission on Intellectual Property Rights, Innovation and Public Health: a call to governments.
    't Hoen E
    Bull World Health Organ; 2006 May; 84(5):421-3. PubMed ID: 16710558
    [No Abstract]   [Full Text] [Related]  

  • 7. Patent laws. Report urges leeway for developing world.
    Couzin J; Bagla P
    Science; 2002 Sep; 297(5588):1791. PubMed ID: 12228696
    [No Abstract]   [Full Text] [Related]  

  • 8. Promoting global health: utilizing WHO to integrate public health, innovation and intellectual property.
    Mackey TK; Liang BA
    Drug Discov Today; 2012 Dec; 17(23-24):1254-7. PubMed ID: 22728776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benchmarking progress in tackling the challenges of intellectual property, and access to medicines in developing countries.
    Musungu SF
    Bull World Health Organ; 2006 May; 84(5):366-70. PubMed ID: 16710545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global health and Brazilian foreign policy: the negotiations on innovation and intellectual property.
    Lima JHDS
    Cien Saude Colet; 2017 Jul; 22(7):2213-2221. PubMed ID: 28724003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of TRIPS on innovation and exports: a case study of the pharmaceutical industry in India.
    Malhotra P
    Indian J Med Ethics; 2008; 5(2):61-5. PubMed ID: 18624153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Patentability of living material: public health concerns (1/2)].
    Manuel C; Hairion D; Antoniotti S; Lafon C; Siméoni MC; Auquier P
    Presse Med; 2002 Oct; 31(34):1591-5. PubMed ID: 12426975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intellectual property rights, the World Trade Organization and public health: the Brazilian perspective.
    Viana JM
    Conn J Int Law; 2002; 17(2):311-8. PubMed ID: 12688298
    [No Abstract]   [Full Text] [Related]  

  • 14. The Inter-Governmental Working Group on Public Health, Innovation and Intellectual Property (IGWG)--the way ahead.
    Satyanarayana K; Srivastava S
    Indian J Med Res; 2008 Nov; 128(5):577-80. PubMed ID: 19179674
    [No Abstract]   [Full Text] [Related]  

  • 15. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
    Allard Soto R
    Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WHO's web-based public hearings: hijacked by pharma?
    Wibulpolprasert S; Moosa S; Satyanarayana K; Samarage S; Tangcharoensathien V
    Lancet; 2007 Nov; 370(9601):1754. PubMed ID: 18022221
    [No Abstract]   [Full Text] [Related]  

  • 17. [Counterfeit and Falsified Drugs: an Overview].
    Taverriti-Fortier C; Pape E; Scala-Bertola J; Tréchot P; Maincent P; Gibaja V; Gambier N
    Therapie; 2015; 70(5):455-64. PubMed ID: 26071144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trade, TRIPS, and pharmaceuticals.
    Smith RD; Correa C; Oh C
    Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternatives to the drug research and development model.
    Velásquez G
    Salud Colect; 2015 Mar; 11(1):23-34. PubMed ID: 25853828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.